Galapagos N.V.

Total net revenues were EUR 6.5 million in Q1 2026, down from EUR 75 million in Q1 2025. R&D expenses were EUR 31 million, operating loss was EUR 63.7 million versus EUR 158.7 million last year, and net financial income was EUR 77.7 million, leading to net profit of EUR 14.5 million versus a net loss of EUR 153.4 million in the first 3 months of 2025. Cash and cash equivalents plus financial investments totaled EUR 2,982.2 million at March 31, 2026. For 2026, management expects EUR 60 million to EUR 75 million of Ouro-related cash expenditures, EUR 125 million to EUR 175 million of one-time cell therapy wind-down costs, and year-end cash of EUR 1.975 billion to EUR 2.05 billion.

Henry Gosebruch framed the quarter as evidence of a broad transformation, saying the company has reshaped management, the board, and the pipeline and is changing its name to Lakefront Biotherapeutics. He was highly upbeat on gamgertamig, calling it a potential first- and best-in-class T cell engager with rapid, durable responses and a path to registrational studies as early as 2027. He also stressed disciplined capital allocation and said the company is focused on building long-term value through business development and execution.

Aaron Cox emphasized the financial flexibility created by the revised Gilead relationship, saying participation was far above the EUR 150 million expected under the legacy agreement and that EUR 500 million is now unlocked for broader use beyond the Ouro investment. He noted that up to EUR 150 million of that pool may be used for return of capital, and said shareholders approved a share repurchase, with an update to follow after closing. On the quarter, he pointed to EUR 6.5 million of revenue, lower R&D expense at EUR 31 million, improved operating loss of EUR 63.7 million, and cash and financial investments of EUR 2,982.2 million at March 31, 2026; he also guided to EUR 775 million to EUR 790 million of total Ouro-related cash expenditures for 2026 including an upfront payment of approximately EUR 713 million.

Analysts focused on what gamgertamig must show to advance into late-stage development, including B-cell depletion depth and durability, CRS risk, infection risk, and how management would choose first registrational indications. Management said the desired profile is profound B-cell depletion with reduced CRS risk, a short enough depletion period to limit infectious risk and IVIG use, and that it expects to be comfortable with Phase III doses by 2027. They also said initial indications are being chosen based on mechanistic hypothesis, unmet need, feasibility, and capital efficiency, while confirming the company is still evaluating strategic options for the 3667 program and is nearing a decision.